Market Movers: Intercept (ICPT) Jumps 6.37% to Close at $13.53 June 23

Equities Staff  |

Today, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rose $0.81 to end the day Thursday at $13.53.

The company began the day at $12.76 and shares fluctuated between $13.55 and $12.45 with 626,890 shares trading hands.

Intercept is averaging 785,093 shares traded over the last 30 days. They have shed 21.92% YTD.

Intercept expects its next earnings on 2022-07-28.

For technical charts, analysis, and more on Intercept visit the company profile.

About Intercept Pharmaceuticals Inc

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

To get more information on Intercept Pharmaceuticals Inc and to follow the company's latest updates, you can visit the company's profile page here: Intercept Pharmaceuticals Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content